Intralipid

Phase 1Small molecule

AstraZeneca

Intralipid is one of 89 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

FunctionCompleted

Vascular DysfunctionRecruiting

Major SurgeryWithdrawn

Metabolic SyndromePreclinical

Active, not recruiting

FunctionPreclinical

Completed

Vascular DysfunctionPhase 1

Recruiting

Major SurgeryPreclinical

Withdrawn

Competition

Competitive Landscape

68 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

6 2

Actos

Takeda

Approved

5 3

Glucophage

EMD Serono

Approved

14 4

Cosentyx

Novartis

Approved

3 5

Avandia

Jazz Pharmaceuticals

Approved

2 6

Lescol

Novartis

Approved

2 7

Bayer Aspirin

Bayer

Approved

1 8

Trexall

Jazz Pharmaceuticals

Approved

1 9

Victoza

Novo Nordisk

Approved

1 10

Plavix

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Metabolic Syndrome

NCT02653092

Q3 2027

Phase 1Recruiting

Vascular Dysfunction

NCT04832009

Clinical

Trials by Indication[1]

Lipid Emulsion3 trials

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Terminated·BBaxter Healthcare Corporation·Phase 4·NCT02476994·1 enrolled

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Completed·BBaxter Healthcare Corporation·Phase 4·NCT04555044·101 enrolled

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

Completed·EEmory University·Phase 2/3·NCT02185729·12 enrolled

Cholestasis2 trials

Preventing Cholestasis Using SMOFLipid®

Completed·MMedical University of Vienna·Phase 4·NCT01585935·230 enrolled

Cholestasis Prevention: Efficacy of IV Fish Oil

Completed·—·Phase 1·NCT00512629·19 enrolled

Miscarriage2 trials

Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial

Withdrawn·WWoman's Health University Hospital, Egypt·Phase 4·NCT01679561

Intralipid for Recurrent Miscarriage

Completed·WWoman's Health University Hospital, Egypt·Phase 4·NCT01788540·300 enrolled

Function1 trial

Effect of Increased Free Fatty Acids on Leptin Function

Completed·—·N/A·NCT01520454·26 enrolled

Homeostasis1 trial

Racial Differences in Vagal Control of Glucose Homeostasis

Completed·VVanderbilt University Medical Center·Phase 1/2·NCT02365285·23 enrolled

18 more indications

Toxicity1 trial

Local Anaesthetics Toxicity and Intralipid®

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01602250·16 enrolled

Lip1 trial

Intralipid for Repeated Implantation Failure

Completed·—·Phase 2/3·NCT01540591·200 enrolled

Liver Disease1 trial

Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders

Terminated·UUniversity of California, Los Angeles·Phase 4·NCT01373918·41 enrolled

CAR1 trial

The Cardioprotective Effect of Intralipid in Decreasing the Ischemic Insults During Off-pump Coronary Artery Revascularization

Completed·—·Phase 4·NCT04806425·46 enrolled

Metabolic Syndrome1 trial

Reprometabolic Syndrome Mediates Subfertility in Obesity

Active, not recruiting·UUniversity of Colorado, Denver·N/A·NCT02653092·84 enrolled

Spontaneous Abortion1 trial

Unknown status·AAhmed Mohamed Bahaa Eldin Ahmed·Phase 1·NCT03132779·34 enrolled

Gastrointestinal Endoscopy1 trial

Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01961349·279 enrolled

Hospitalized Patients1 trial

Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils

Completed·JJohane Allard·Phase 4·NCT01943409·303 enrolled

Musculoskeletal1 trial

Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health

Withdrawn·—·Phase 2·NCT03127345

Coronary Artery Bypass1 trial

Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting

Terminated·MMeshalkin Research Institute of Pathology of Circulation·Phase 3·NCT01175330·39 enrolled

Major Surgery1 trial

Lipid Infusion Following Major Surgery

Withdrawn·UUniversity of Alberta·N/A·NCT02463812

Vascular Dysfunction1 trial

Reversing Glucose and Lipid-mediated Vascular Dysfunction

Recruiting·UUniversity of Kansas Medical Center·Phase 1·NCT04832009·46 enrolled

Hepatic Function1 trial

Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01786759·100 enrolled

ESS1 trial

Determining the Responsiveness of Intestinal Lipoprotein Production to an Elevation of Plasma Free Fatty Acids

Completed·UUniversity Health Network, Toronto·N/A·NCT00152945·10 enrolled

Obesity1 trial

Neuroimmune Mechanisms in Obesity

Withdrawn·YYale University·Phase 1·NCT05553405

Intracytoplasmic Sperm Injection1 trial

Intralipid Therapy for Women 35-40 Years With Positive Natural Killer Cells Undergoing Intracytoplasmic Sperm Injection (ICSI)

Terminated·—·Phase 3·NCT01916798·200 enrolled

Type 2 Diabetes1 trial

Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)

Completed·PPennington Biomedical Research Center·Phase 1·NCT02697201·25 enrolled

Parenteral Nutrition1 trial

Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants

Unknown status·WWei Cai·Phase 4·NCT01683162·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Intralipid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intralipid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intralipid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

Intralipid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Lipid Emulsion3 trials

Cholestasis2 trials

Miscarriage2 trials

Function1 trial

Homeostasis1 trial

Toxicity1 trial

Lip1 trial

Liver Disease1 trial

CAR1 trial

Metabolic Syndrome1 trial

Spontaneous Abortion1 trial

Gastrointestinal Endoscopy1 trial

Hospitalized Patients1 trial

Musculoskeletal1 trial

Coronary Artery Bypass1 trial

Major Surgery1 trial

Vascular Dysfunction1 trial

Hepatic Function1 trial

ESS1 trial

Obesity1 trial

Intracytoplasmic Sperm Injection1 trial

Type 2 Diabetes1 trial

Parenteral Nutrition1 trial

References

Drug Info

Quick Facts

Related News